CION Ameerpet
Ductal carcinoma in situ (DCIS) is the earliest form of breast cancer — stage 0. The abnormal cells sit inside a milk duct and have not spread into the surrounding breast tissue, so DCIS is non-invasive and cannot spread to the rest of the body. It is one of the most curable diagnoses in all of cancer care: nearly everyone treated for DCIS is alive and well 20 years later. At CION Cancer Clinics in Hyderabad, our tumor board helps you understand your grade, weigh treatment options calmly, and avoid both under- and over-treatment — with a free first consultation.
Ductal carcinoma in situ (DCIS) is the earliest stage of breast cancer, which is why it is called stage 0. The word "in situ" is Latin for "in its original place": the abnormal cells are still inside a milk duct and have not broken through the duct wall into the surrounding breast tissue. Because of this, DCIS is non-invasive — it cannot spread to the lymph nodes or to the rest of the body the way invasive breast cancer can.
So is it really cancer? The honest answer is yes and no — and understanding this removes a lot of fear. The cells are cancer cells, so doctors and pathologists classify DCIS as a breast cancer. But because it stays trapped inside the duct, it is not life-threatening on its own. Many people find it helpful to think of DCIS as "pre-invasive" — a very early warning that is highly treatable, rather than the aggressive disease most people picture when they hear the word cancer. About 1 in 5 new breast cancer diagnoses in the world is DCIS, almost all of them found on screening mammograms.
The reason DCIS is treated at all is that, left alone, some cases would over time turn into invasive cancer — and today we cannot perfectly predict which ones. At CION, our tumor board explains exactly where your DCIS sits on that spectrum, so the plan matches your real risk and you are neither alarmed nor over-treated.
The cells are confined inside the milk duct and have not invaded the breast tissue around it.
On its own, DCIS cannot spread to lymph nodes or the body — so it is not life-threatening.
Classed as breast cancer, yet the earliest and most curable form — best thought of as pre-invasive.
About 1 in 5 new breast cancer diagnoses is DCIS, and almost all are picked up on a screening mammogram — not as a lump. Stage 0 disease has an outstanding outlook: nearly everyone treated for DCIS is alive 20 years later. Source: American Cancer Society / SEER breast-cancer data.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
DCIS almost never causes a lump or pain. The great majority of cases are screen-detected — picked up on a routine mammogram in a woman with no symptoms at all. This is why regular breast screening matters so much: it finds breast cancer at its most curable, stage 0 point, often years before it could ever be felt. The classic clue a radiologist looks for is micro-calcifications: tiny white flecks of calcium that appear in characteristic clusters or lines on the mammogram. They are far too small to feel and are usually harmless, but certain patterns suggest DCIS and prompt a closer look. When DCIS is suspected, a short, ordered diagnostic pathway follows — at CION, with no unnecessary tests along the way.
Most DCIS is found on a routine screening mammogram in a woman with no lump, pain or visible change — which is exactly why regular screening is so valuable. Catching breast cancer at stage 0, before it can be felt, gives the best possible outcome.
The commonest sign of DCIS is a cluster or line of micro-calcifications — minute calcium deposits seen as white flecks. Their shape and pattern matter: fine, granular flecks tend to suggest lower-grade DCIS, while pleomorphic (irregular) patterns more often point to high-grade disease.
If screening flags suspicious calcifications, you are recalled for a diagnostic mammogram with magnification views. These higher-detail images let the radiologist map exactly how widespread the calcifications are, which guides both the biopsy and, later, the choice between lumpectomy and mastectomy.
In women with dense breasts, or when the extent of disease is unclear, a breast ultrasound or MRI may be added. MRI is particularly useful for showing how far DCIS reaches within the ducts, which helps the surgical team plan margins and decide whether breast-conserving surgery is feasible.
Diagnosis is confirmed with a core-needle biopsy, usually guided by mammography (stereotactic) to target the exact calcifications. A small tissue sample is taken under local anaesthetic and sent to pathology. This is far less invasive than surgery and tells us whether the cells are DCIS, invasive cancer, or benign.
An expert breast pathologist examines the biopsy to confirm DCIS, assign its grade (low, intermediate or high), and test for hormone (oestrogen/ER) receptors. This report is the foundation of your whole treatment plan, so at CION it is reviewed carefully — and re-reviewed at our tumor board — before anything is decided.
All DCIS is stage 0, but not all DCIS behaves the same way. Under the microscope, the pathologist assigns a grade based on how abnormal the cells look and how quickly they appear to be dividing. The grade is one of the single most important pieces of information in your report, because it strongly influences how likely the DCIS is to come back or progress — and therefore how much treatment you need.
There are three grades. Low-grade (grade 1) DCIS cells look only slightly different from normal cells, grow slowly, and carry the lowest risk of recurrence. Intermediate-grade (grade 2) sits in between. High-grade (grade 3) cells look clearly abnormal, grow faster, and have the highest chance of returning or, if untreated, turning invasive — sometimes within just a few years. High-grade DCIS may also show "comedo necrosis" (areas of dead cells), another feature that signals a more active disease. Knowing your grade is what lets CION's tumor board right-size your treatment — sparing low-grade patients unnecessary intervention while giving high-grade DCIS the thorough treatment it deserves.
Cells look almost normal, grow slowly, lowest recurrence risk — often the least intensive treatment.
An in-between appearance and growth rate, with a moderate risk of recurrence.
Clearly abnormal, faster-growing, highest recurrence and progression risk — treated more thoroughly.
A stage 0 diagnosis sounds frightening, but it is genuinely good news — and the worst thing that can happen now is a rushed or excessive decision. As a woman-headed, tumor-board-led organisation, CION was built to handle exactly this: an early, highly curable cancer where the real skill is matching treatment precisely to risk. Every DCIS case is reviewed together by surgical, medical and radiation oncologists, so you get a panel's judgement, not one doctor's habit. Consultations run a full 45 minutes, with no unnecessary tests and clear, transparent costs.
With 150+ years of combined oncology experience, 17 super-specialist oncologists and 35+ centres across Telangana and AP, CION has guided more than 15,000 patients and earned a 4.8/5 Google rating across its centres. For breast cancer overall, CION's outcomes lead the national average — a 96.9% one-year survival rate at CION versus 85.4% nationally* — and for stage 0 disease the outlook is better still.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Free first consultation. Confidential, tumor-board-led guidance at CION Cancer Clinics, Hyderabad. Call us: 1800-202-8726.
Treatment for DCIS is highly effective and, importantly, individualised — the right plan depends on the size and grade of your DCIS, where it sits, and your own preferences. Surgery is almost always the first step, and there are two paths. One reassuring point upfront: chemotherapy is not used for DCIS, because the disease has not spread and there is nothing for chemotherapy to chase through the body. At CION, your exact combination is decided at the tumor board so you receive enough treatment to be cured — and no more than that.
The most common DCIS surgery: the area of DCIS plus a margin of healthy tissue is removed while the rest of the breast is kept. It is suitable when the DCIS is contained to one area, and it preserves the natural breast. The pathologist checks the margins to confirm all the DCIS has been removed.
For most patients, a short course of radiation after lumpectomy is recommended. Radiation does not change survival (which is already excellent) but it markedly lowers the chance of DCIS returning — either as DCIS again or as invasive cancer — in the conserved breast. It is the standard breast-conserving combination worldwide.
In carefully chosen patients — small, low-grade DCIS removed with clear, wide margins, often in older women — radiation may safely be skipped. This avoids unnecessary treatment in genuinely low-risk disease. Genomic tests such as Oncotype DX DCIS can help estimate recurrence risk and guide this decision at the tumor board.
A mastectomy (removing the whole breast) is advised when DCIS is widespread, present in several areas of the breast, or too large to remove with a good cosmetic result, or when radiation must be avoided. It offers the lowest recurrence risk of all — under 2% — and breast reconstruction can usually be done at the same operation.
If your DCIS is oestrogen-receptor-positive (ER+), a daily tablet such as tamoxifen or an aromatase inhibitor for about five years can further lower the risk of a new or recurrent breast cancer in either breast. It is optional, the benefits and side-effects are weighed individually, and it is never given for ER-negative DCIS.
Because DCIS is non-invasive and cannot spread, chemotherapy plays no role in its treatment. This is one of the most reassuring facts about a stage 0 diagnosis — treatment is local (surgery, sometimes radiation) plus, for ER+ disease, an optional hormone tablet, with no chemotherapy and its side-effects.
This is the question almost every patient asks, and it deserves a clear, honest answer. DCIS does not always turn into invasive cancer — many cases would never progress in a person's lifetime. But some would, and at present medicine cannot perfectly tell, for any individual, which path their DCIS would take. Studies of untreated or under-recognised DCIS estimate that somewhere between roughly 20% and 50% would eventually become invasive over 10–15 years if left alone — meaning a large share would not. Because the consequences of progression are serious and the prediction is imperfect, the standard approach is to treat DCIS now, while it is stage 0 and almost always curable.
What changes the odds is mostly the grade: high-grade DCIS is more likely to progress, and faster, than low-grade DCIS. This is exactly why grade-based, individualised planning matters — and why the field is actively studying whether some very-low-risk patients can safely be monitored instead of operated on (active surveillance trials such as COMET and LORIS are ongoing). At CION, we explain your personal risk in plain terms, present the evidence without alarm, and let you make a calm, informed choice with the tumor board's guidance.
Many cases would never become invasive in a lifetime — but we cannot yet predict which ones with certainty.
High-grade DCIS is more likely to progress, and sooner; low-grade is least likely. This shapes your plan.
Because progression can't be perfectly predicted, treating early keeps the disease at its most curable point.
Trials (COMET, LORIS) are testing whether some very-low-risk DCIS can be safely monitored — we share the latest evidence.
If there is one message to take from this page, it is this: the outlook for DCIS is excellent. Because stage 0 disease has not spread, the prognosis after treatment is among the best in all of cancer care. Large studies show that around 98% of people are alive 10 years after a DCIS diagnosis, and nearly everyone treated for DCIS is alive 20 years later. Death from DCIS is rare. The main thing treatment guards against is not death but recurrence — the small chance of DCIS or an invasive cancer appearing in the future — and modern treatment keeps that risk low.
Recurrence risk depends on the treatment you had. After lumpectomy with radiation, the chance of the cancer returning in that breast is roughly 5–15% over many years; after mastectomy it is under 2%. Most recurrences, if they happen at all, occur within the first 10 years. That is why follow-up matters: regular clinical examinations and an annual mammogram of the remaining breast tissue let any change be caught early, when it is again highly treatable. If you took hormone therapy, your team will also review it periodically. At CION, follow-up is a structured, ongoing plan with your team — not a one-off discharge.
Stage 0 prognosis is outstanding — nearly everyone treated for DCIS is alive 20 years on, and death is rare.
Roughly 5–15% after lumpectomy + radiation; under 2% after mastectomy — most within the first 10 years.
Regular exams and yearly mammography catch any change early, when it is again highly treatable.
A stage 0 diagnosis calls for clear thinking, not panic — and CION's pathway is built for exactly that. It begins with an expert pathology review of your biopsy to confirm the diagnosis, grade and receptor status, because so much of the plan rests on getting this right. Your case then goes to our tumor board, where surgical, medical and radiation oncologists agree on a recommendation together. In your unhurried 45-minute consultation we lay out every reasonable option — lumpectomy with or without radiation, mastectomy, and hormone therapy if you are ER-positive — with transparent costs and no pressure. Decisions are made for healing, not billing.
As a woman-headed organisation with 150+ years of combined experience, 17 super-specialist oncologists, 35+ centres across Telangana and AP and a 4.8/5 Google rating, CION has supported more than 15,000 patients and families. For one of breast cancer's most curable diagnoses, you deserve a calm, expert, team-led plan — and your first consultation is free.
Hear from women diagnosed with early breast cancer who made confident, unhurried choices with CION's tumor-board-led team.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.DCIS is made of cancer cells, so doctors classify it as breast cancer — the very earliest form, called stage 0. But "in situ" means the cells are still inside a milk duct and have not broken through into the surrounding breast tissue. Because it is non-invasive, DCIS cannot spread to the lymph nodes or the rest of the body, and on its own it is not life-threatening. Many people find it clearer to think of DCIS as "pre-invasive": a highly treatable early warning rather than the aggressive disease most people picture when they hear the word cancer. It is treated because, left alone, some cases would eventually turn invasive — and treating it now keeps it at its most curable stage.
Most DCIS causes no lump, pain or visible change, so it is almost always found on a routine screening mammogram in a woman with no symptoms. The classic clue is micro-calcifications — tiny white flecks of calcium that appear in suspicious clusters or lines on the mammogram. If these are seen, you are recalled for a diagnostic mammogram with magnification views, and sometimes an ultrasound or breast MRI to map how widespread the area is. The diagnosis is then confirmed with an image-guided core-needle biopsy, taken under local anaesthetic, which a breast pathologist examines to confirm DCIS, assign its grade and test for hormone receptors. This is exactly why regular breast screening matters — it catches breast cancer at its most curable, stage 0 point.
Grade describes how abnormal the DCIS cells look under the microscope and how fast they appear to be growing. Low-grade (grade 1) cells look almost normal, grow slowly and carry the lowest risk of coming back. Intermediate-grade (grade 2) sits in between. High-grade (grade 3) cells look clearly abnormal, grow faster, and have the highest chance of recurring or, if untreated, becoming invasive — sometimes within a few years; high-grade DCIS may also show areas of dead cells called comedo necrosis. Grade is one of the most important details in your report because it strongly influences how much treatment you need. At CION, your grade lets the tumor board right-size treatment — sparing low-grade patients unnecessary intervention while treating high-grade disease thoroughly.
Surgery is almost always the first step. Most patients have a lumpectomy (breast-conserving surgery), which removes the DCIS plus a margin of healthy tissue and keeps the rest of the breast; this is usually followed by a short course of radiation to lower the chance of it returning. In selected low-risk cases — small, low-grade DCIS with clear margins, often in older women — radiation may safely be skipped. A mastectomy (removing the whole breast) is advised when DCIS is widespread or too large for a good lumpectomy result, and it carries the lowest recurrence risk. If the DCIS is oestrogen-receptor-positive (ER+), an optional hormone tablet such as tamoxifen or an aromatase inhibitor for about five years can further reduce risk. Importantly, chemotherapy is not used for DCIS, because it has not spread.
No. Chemotherapy is not part of DCIS treatment. Chemotherapy works throughout the whole body to chase cancer cells that may have spread — but DCIS is non-invasive and confined to the milk duct, so there is nothing for chemotherapy to chase. This is one of the most reassuring facts about a stage 0 diagnosis. DCIS treatment is local: surgery (lumpectomy or mastectomy), often with radiation after breast-conserving surgery, and — only if the DCIS is hormone-receptor-positive — an optional daily hormone tablet to lower future risk. You avoid chemotherapy and its side-effects entirely. At CION, your exact combination is decided by the tumor board so you receive enough treatment to be cured and no more than that.
Not always. Many cases of DCIS would never become invasive in a person's lifetime — but some would, and medicine cannot yet predict with certainty which path any individual's DCIS will take. Studies estimate that roughly 20–50% of untreated DCIS would eventually become invasive over 10–15 years, meaning a large share would not. The grade matters most: high-grade DCIS is more likely to progress, and sooner, than low-grade. Because the consequences of progression are serious and the prediction is imperfect, the standard advice is to treat DCIS now, while it is stage 0 and almost always curable. The field is actively studying whether some very-low-risk patients can be safely monitored instead (trials such as COMET and LORIS), and CION shares this evidence with you honestly.
The prognosis for DCIS is excellent — among the best in all of cancer care. Because stage 0 disease has not spread, large studies show around 98% of people are alive 10 years after diagnosis, and nearly everyone treated for DCIS is alive 20 years later. Death from DCIS is rare. The main thing treatment guards against is recurrence rather than death: after lumpectomy with radiation, the chance of cancer returning in that breast is roughly 5–15% over many years, and after mastectomy it is under 2%. Most recurrences, if they happen, occur within the first 10 years. Regular follow-up with clinical exams and an annual mammogram keeps any change caught early, when it is again highly treatable.
Yes — follow-up is an important, ongoing part of DCIS care, not a one-off discharge. It typically involves regular clinical breast examinations and an annual mammogram of the remaining breast tissue, so any new change is found early. If you took hormone therapy, your team will review it periodically too. To start at CION, book a free first consultation online or call 1800-202-8726. Your appointment is an unhurried, 45-minute conversation: we review (or arrange an expert review of) your pathology, bring your case to the tumor board, and explain every option — lumpectomy with or without radiation, mastectomy, and hormone therapy if you are ER-positive — with transparent costs and no pressure. Decisions are made for healing, not billing.